Cara Therapeutics (CARA) : The highest short term price target forecast on Cara Therapeutics (CARA) is $24 and the lowest target price is $16. A total of 4 equity analysts are currently covering the company. The average price of all the analysts is $20.5 with a standard deviation of $4.12.
Cara Therapeutics (CARA) has an average broker rating of 1, which is interpreted as a Strong Buy, as rated by 4 equity analysts. Nonetheless, 4 analysts are positive on the stocks future and they recommend a Strong Buy on the stock. Ranking by Zacks Investment Research for Coach Inc is 4, which is also a Sell.
Also, Equity Analysts at the Brokerage Firm, Stifel Nicolaus, maintains their rating on the shares of Cara Therapeutics (NASDAQ:CARA). Stifel Nicolaus has a Buy rating on the shares. As per the latest research report, the brokerage house lowers the price target to $24 per share from a prior target of $25. The rating by the firm was issued on August 5, 2016.
Cara Therapeutics (NASDAQ:CARA): The stock opened at $5.39 on Thursday but the bulls could not build on the opening and the stock topped out at $5.47 for the day. The stock traded down to $5.30 during the day, due to lack of any buying support eventually closed down at $5.38 with a loss of -0.74% for the day. The stock had closed at $5.42 on the previous day. The total traded volume was 260,308 shares.
Cara Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing chemical entities designed to alleviate pain and pruritus by focusing on kappa opioid receptors. The Company is engaged in developing product candidates that focus on the bodys peripheral nervous system. Its product candidate pipeline includes I.V. CR845 for acute pain; I.V. CR845 for uremic pruritus; Oral CR845 for acute and chronic pain, and CR701 for neuropathic and inflammatory pain. CR845 is a peripherally-acting kappa opioid receptor agonist for the treatment of both acute and chronic pain. I.V. CR845 is an injectable version of its peripheral kappa opioid receptor agonist, which is designed to provide pain relief without stimulating mu opioid receptors. CR701 is a peripherally-restricted, mixed-CB1/CB2 receptor agonist that interacts with these cannabinoid receptor subtypes, with no off-target activities.